Braf kinase inhibitors market

BRAF is a kinase enzyme that helps control cell growth and signaling. It may be found in a mutated (changed) form in some types of cancer, including melanoma and colorectal cancer. Blocking mutated BRAF kinase proteins helps to stop the cancer cells from growing. Some BRAF kinase inhibitors are used to treat cancer. Product approvals by regulatory bodies in various regions across the globe are expected to drive growth of the market during the forecast period. For instance, in July 2020, Roche announced that the U.S. Food and Drug Administration approved Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients.

BRAF Kinase Inhibitors Market – Impact of Coronavirus (Covid-19) Pandemic

As the novel coronavirus has spread across the globe, it has created profound disruption across communities, hospitals, and other healthcare settings, and the way it works. Product development has experienced disruption, as researchers have to adjust to remote work environments and lab capacity is reduced. Clinical trials are also being severely affected with disruptions in both new enrollment and in keeping existing patients on therapies. According to the clinicaltrial.gov, as of April 2020, there were more than 2,850 trials and approximately 900,000 patients enrolled at trial sites in regions that were in partial or complete lockdown due to COVID-19 restrictions. The R&D labs are operating at below 50% of normal capacity.

The BRAF kinase inhibitors market is estimated to be valued at US$ 924.8 million in 2020 and is expected to exhibit a CAGR of 8.6% during the forecast period (2020-2027).

Figure 1. Global BRAF Kinase Inhibitors Market Share (%) Analysis, By Drug 2020

The robust pipeline for treatment of metastatic cancers and increasing prevalence of cancer are expected to boost growth of the BRAF kinase inhibitors market

Several companies have ongoing clinical trials of BRAF kinase inhibitors drugs. The robust pipeline of BRAF kinase inhibitor drugs is expected to significantly drive growth of the global BRAF kinase inhibitors market in the near future. For instance, in June 2020, BeiGene, Ltd., a commercial-stage biotechnology company and SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the presentation of preclinical data and provided a program update on their ongoing Phase 1b/2 study evaluating the combination of BeiGene’s investigational RAF dimer inhibitor, lifirafenib, with SpringWorks’ investigational MEK inhibitor, mirdametinib, in patients with advanced or refractory solid tumors harboring mutations in the MAPK pathway, including those with RAS mutations.

Furthermore, BRAF kinase inhibitors market is expected to witness high growth over the forecast period, owing to increasing incidence and prevalence of metastatic cancer. For instance, according to the Centers for Disease Control and Prevention provided data for 2012 to 2016, around 77,698 new cases of melanoma cancer (45,854 among men and 31,845 among women) were diagnosed every year in the U.S. Moreover, the American Cancer Society estimated that around 100,350 new cases of melanoma will be diagnosed and around 6,850 deaths are estimated to occur due to melanoma in the U.S. in 2020. Hence, such drivers are expected to positively impact the global BRAF kinase inhibitors market growth.

BRAF Kinase Inhibitors Market – Restraints

Medications and surgical operations are used to prevent or slow down further damage from occurring. Extensive R&D activities and manufacturing makes the drugs very expensive, which is expected to hamper the BRAF kinase inhibitors market growth over the forecast period. For instance, according to data published in National Center for Biotechnology Information (NCBI), by Experimental Hematology & Oncology, by year 7 of metastatic cancer, the cumulative costs per month were US$ 4,281 for ipilimumab, compared to US$ 8,920 for dabrafenib, US$ 10,211 for trametinib, US$ 11,002 for vemurafenib, and US$ 19,132 for dabrafenib + trametinib combination therapy.

BRAF Kinase Inhibitors Market – Regional Analysis

North America is estimated to hold the dominant position in 2020 in the global BRAF kinase inhibitors market. Increasing number of product approvals by the regulatory authorities is a major factor that propels growth of the North America BRAF kinase inhibitors market. For instance, in July 2020, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor atezolizumab (Tecentriq) plus the MEK inhibitor cobimetinib (Cotellic) and the selective BRAF kinase inhibitor vemurafenib (Zelboraf) for the treatment of patients with advanced BRAF V600 mutation–positive melanoma. The approval is based on results from IMspire150, a multicenter, double-blind, placebo-controlled randomized phase III study.

Moreover, Europe BRAF kinase inhibitors market is also expected to gain momentum over the forecast period. For instance, in September 2018, Pierre Fabre announced that the European Commission (EC) granted marketing authorization for the combination of BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation, as detected by a validated test. The EC decision is applicable to all 28 European Union (EU) member states and Liechtenstein, Iceland, and Norway.

Figure 2. Global BRAF Kinase Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027

BRAF Kinase Inhibitors Market - Competitive Landscape

Key players operating in the global BRAF kinase inhibitors market include F. Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc.